Eric Keller, J.D. Chief Executive Officer, Founder & Chairman

Eric Keller is the Founder and CEO of Retension Pharmaceuticals. He also serves as the Founder and CEO of Redux Therapeutics, a company focused on therapeutic asset acquisition and development. With nearly 30 years of experience in life sciences companies, Mr. Keller previously served as CEO of Nano Terra, where he oversaw the acquisition of Surface Logix and the subsequent out-licensing of three Phase 2 small molecule drugs, including RezuRock (now marketed by Sanofi) and RTN-001.

Alex Schwartz, M.B.A. Chief Financial Officer

Alex Schwartz brings over 15 years of financial expertise from both corporate and Wall Street sectors, specializing as a biotechnology equity research analyst and finance executive providing strategic guidance to biotech firms. He has successfully raised over $500 million in capital. Most recently, he was the Vice President of Financial Planning & Analysis and Investor Relations at Ventyx Biosciences, Inc., which was acquired by Eli Lilly and Company in March 2026. Mr. Schwartz's background includes senior finance and investor relations roles at Allakos Inc., NGM Biopharmaceuticals, Inc., and Esperion Therapeutics, Inc., where he provided financial and strategic leadership for clinical development, regulatory approvals, and commercial launches.

Paul Sweetnam, Ph.D. Chief Scientific Officer & Co-Founder

Paul Sweetnam has over 25 years of experience in senior scientific and management roles within the pharmaceutical and biotechnology industries. He led the discovery of RTN-001 at Surface Logix, Inc., and was instrumental in advancing eight candidate molecules into clinical development during his tenure at Bayer Healthcare, including Nexavar.

Alison D. Schecter, M.D. Chief Medical Officer

Alison D. Schecter is a physician-scientist with more than 25 years of experience in inflammation and cardiometabolic diseases, holding board certifications in Internal Medicine and Cardiology. Prior to joining Retension, she was the Senior Vice President and Head of Clinical Development at Mineralys Therapeutics, where she oversaw multiple registration trials for resistant hypertension. Dr. Schecter's extensive leadership experience includes roles as CEO of Molecules to Medicine Advisory Group, President of Research and Development at Axcella Health Inc., and Chief Medical Officer at Selecta Biosciences. She also played a central role in securing FDA approvals for Xenpozyme® at Sanofi-Genzyme and Adynovate® at Baxalta.

Sabine Bisson, Ph.D. Chief Operating Officer

Sabine Bisson brings nearly 20 years of strategic and operational leadership experience from various biotech companies, where she has overseen development and partnership activities across the R&D lifecycle. She was instrumental in the development of several therapeutics, including the CV metabolism drug Praluent® and the Immuno-Oncology agent Libtayo®. Her prior roles include leading programs at Regeneron, Cellectis, and Volastra.

The key risks to Retension Pharmaceuticals (RTSN) primarily revolve around its status as a clinical-stage biopharmaceutical company with a single lead product candidate.

1. Clinical Trial and Regulatory Approval Risk: As a clinical-stage company, Retension Pharmaceuticals' success is heavily dependent on the successful completion of clinical trials for its lead candidate, RTN-001, and subsequent regulatory approval. The company is currently in a Phase 2b trial for RTN-001, with initial data anticipated in the first half of 2027. Failure at any stage of clinical development, or the inability to secure regulatory approvals from health authorities like the FDA, would severely impact the company's viability.
2. Reliance on a Single Product Candidate: Retension Pharmaceuticals' entire business strategy is centered on the development and potential commercialization of a single asset, RTN-001. Should RTN-001 fail to achieve its clinical endpoints, demonstrate an unfavorable safety profile, or not gain market acceptance, the company lacks other pipeline products to diversify its risk, making it highly vulnerable to the success or failure of this one drug.
3. Competition and Market Acceptance: The market for hypertension treatments is highly competitive, with numerous established drug classes already available, including ACE inhibitors, ARBs, calcium channel blockers, diuretics, and beta blockers, as well as other emerging cardiometabolic approaches. Even if RTN-001 successfully navigates clinical trials and receives regulatory approval, it will need to demonstrate significant advantages in efficacy, safety, or patient convenience to effectively compete and gain meaningful market share against these entrenched therapies.

Retension Pharmaceuticals (RTSN) is a clinical-stage biopharmaceutical company primarily focused on developing RTN-001, a lead drug candidate for the treatment of uncontrolled and resistant hypertension.

The addressable market for hypertension, the condition RTN-001 aims to treat, is substantial:

• Globally, it is estimated that as much as 20% of the population suffers from hypertension.
• In the U.S., nearly one-half of the adult population is affected by hypertension, amounting to approximately 120 million adults.

For Retension Pharmaceuticals (symbol: RTSN), a clinical-stage biopharmaceutical company with its lead candidate RTN-001 in development for hypertension, the primary drivers of future revenue growth over the next 2-3 years are tied to its clinical development milestones and strategic positioning, rather than immediate product sales, as the company is currently pre-revenue.

Here are 3-5 expected drivers of future revenue growth:

1. Advancement of RTN-001 through Clinical Development: The successful progression of RTN-001, a next-generation PDE-5 inhibitor for uncontrolled and resistant hypertension, through its ongoing Phase 2b clinical trials and into subsequent Phase 3 trials is a critical driver. Initial data from the Phase 2b trial is anticipated in the first half of 2027. Positive clinical outcomes are essential for the drug to move closer to market, thereby increasing its future revenue potential.
2. Securing Regulatory Approval for RTN-001: Achieving significant progress toward or ultimately gaining regulatory approval (e.g., from the FDA) for RTN-001 within the 2-3 year timeframe would be a pivotal event. Although direct commercial sales might not generate substantial revenue immediately within this short period, regulatory approval would de-risk the asset, unlock its commercialization pathway, and significantly increase the company's valuation and long-term revenue prospects.
3. Expansion into New Indications for RTN-001: Retension Pharmaceuticals is exploring additional cardiovascular or renal indications where the nitric oxide-cGMP pathway modulation offered by RTN-001 could be beneficial. Initiating clinical development for these expanded indications would broaden RTN-001's potential market reach and establish additional future revenue streams beyond its initial focus on hypertension.
4. Strategic Partnerships and Licensing Deals: As a clinical-stage company, securing new strategic partnerships or licensing agreements for RTN-001 could provide essential non-dilutive funding, milestone payments, and potential future royalties on sales. These collaborations can accelerate development, mitigate financial risk, and leverage larger partners' commercialization capabilities, thereby generating "revenue" in the form of payments and enhancing the overall value proposition that leads to future product revenue.

Share Issuance

• Retension Pharmaceuticals filed for an Initial Public Offering (IPO) on September 18, 2026, aiming to raise up to $58 million (with estimated proceeds of $60 million) by listing on the Nasdaq under the symbol RTSN.

Inbound Investments

• Retension Pharmaceuticals has raised a total of $22.4 million in funding.
• The company successfully closed a $10.4 million Series A financing round on August 23, 2024, to launch a Phase 2 clinical study for RTN-001 and support ongoing development efforts.
• On August 7, 2025, Retension Pharmaceuticals completed a $15 million Series B financing round to advance the clinical development of RTN-001.

Capital Expenditures

• Proceeds from the anticipated IPO are earmarked to complete the Phase 2b clinical trial and prepare for the planned Phase 3 trial of its lead candidate, RTN-001.
• The $10.4 million Series A financing in August 2024 was allocated to conducting an efficacy study for RTN-001 and supporting the company's development efforts.
• The $15 million Series B financing in August 2025 was specifically for the initiation of a multicenter, double-blind, placebo-controlled, randomized Phase 2b clinical study for RTN-001 in patients with uncontrolled and resistant hypertension, which commenced in Q4 2025.